Sequella has licensed its B-SMART technology to Laboratory Corporation of America (LabCorp) to allow LabCorp to develop a new laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis and to use the assay in the US commercially.
Using B-SMART, LabCorp will develop assay that will combine nucleic acid testing with phage-based technology to recognise any resistance of M. tuberculosis clinical isolates to antitubercular antibiotics, irrespective of whether the resistance genotype is known.
Sequella has retained all rights to commercialize B-SMART technology worldwide for indications other than tuberculosis and for territories outside US for tuberculosis.
The technology suits any nucleic acid detection system, which can be used to develop tests that detect resistance to any drug.
Sequella CEO Carol Nacy said Sequella is happy to sign the first partnership for B-SMART technology with LabCorp.
"We look forward to a successful collaboration and a timely introduction by LabCorp of a new assay that can facilitate appropriate drug selection by physicians treating tuberculosis in this country," Nacy added.
